Merial Limited

Institut National De La Sante Et De La Recherche Medicale

Aventis Pasteur Limited

Other

Pasteur Merieux Serums & Vaccins

Annabelle Bouchardon

Jean-Christophe Francis Audonnet

Michel Albert Riviere

Philippe Guy Baudu

Luc Aujame

Xavier Nassif

Bachra Rokbi

Colin Tinsley

Geneviève Renauld-Mongenie

Agnès Perrin

Regis Sodoyer

Agn&egrave;s Perrin

Frederique Geoffroy

Genevi&egrave;ve Renauld-Mongenie

The invention concerns nucleic acids coding for polypeptides specific of thegenus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.

[object Object]

Disclosed are plasmids that contain and express in vivo in a feline host cell nucleic acid molecules. The plasmid can include nucleic molecule(s) having sequence(s) encoding infectious peritonitis virus M; feline immunodeficiency virus env, or gag, or pro, or gag and pro, or env and gag and pro; rabies G; or feline leukemia virus env and/or gag. Compositions containing such plasmids, methods of use employing such plasmids, and kits involving such plasmids, are also disclosed.

Feline polynucleotide vaccine formula

Disclosed is an immunological or vaccine composition that includes at least one plasmid that contains and expresses in vivo in host canine cells a nucleic acid molecule that encodes an antigen of a canine pathogen, such as rabies G. The plasmid can include more that one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.

Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies

The invention concerns nucleic acids coding for polypeptides specific of the genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.

Nucleic acids and polypeptides specific of the neisseria genus pathogenic strains

Disclosed and claimed are compositions for inducing in a bovine host an immunological response against bovine respiratory syncytial virus or bovine viral diarrhea virus containing at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine respiratory syncytial virus F protein, or G protein, or F and G proteins; or, at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine viral diarrhea virus E2 protein, or C, E1 and E2 proteins, or E1 and E2 proteins. Methods and kits employing such compositions are also disclosed.

Polynucleotide vaccine formula in particular against bovine respiratory pathology

Disclosed is an immunological or vaccine composition that includes at least one plasmid that contains and expresses in vivo in host canine cells a nucleic acid molecule that encodes an antigen of a canine pathogen, such as rabies G. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.

Disclosed and claimed is: an immunogenic or vaccine composition for inducing in an avian host an immunological response against avian pathologies containing at least one plasmid that contains and expresses in vivo in an avian host cell nucleic acid molecule(s) having sequence(s) encoding antigen(s) of the avian pathogen(s); and, methods for using and kits employing such compositions.

Polynucleotide vaccine formula against porcine reproductive and respiratory pathologies

Disclosed and claimed is: an immunogenic or vaccine composition for inducing in an equine host an immunological response against equine pathologies containing at least one plasmid that contains and expresses in vivo in an equine host cell nucleic acid molecule(s) having sequence(s) encoding antigen(s) of the equine pathogen(s); and, methods for using and kits employing such compositions.

Polynucleotide vaccine formulation against pathologies of the horse

An avian plasmid vaccine contains a plasmid, and a pharmaceutically acceptable carrier. The plasmid contains and expresses in vivo in an avian host cell a nucleic acid molecule having a sequence encoding the Newcastle disease virus HN protein. The plasmid can further contain and express in vivo in an avian host cell a nucleic acid molecule having a sequence encoding the Newcastle disease virus F protein.

Avian polynucleotide vaccine formula

Disclosed is an immunological composition that includes at least two plasmids; each plasmid contains and expresses in vivo in host canine cells a nucleic acid molecule that encodes an antigen of a canine pathogen. The plasmids can include more than one nucleic acid molecule such that the plasmids can express more than one antigen. The composition can include a first plasmid that contains and expresses a nucleic acid molecule encoding canine parvovirus VP2 and a second plasmid that contain(s) and express(es) nucleic acid molecule(s) encoding canine distemper HA and/or F.

Polynucleotide vaccine formula against canine pathologies

The avian vaccine formula comprises at least three polynucleotide vaccine valencies each comprising a plasmid integrating, so as to express it in vivo in the host cells, a gene with one avian pathogen valency, these valencies being selected from the group consisting of Marek's disease virus, Newcastle disease virus, infectious bursal disease virus, infectious bronchitis virus, infectious anaemia virus, the plasmids comprising, for each valency, one or more of the genes selected from the group consisting of gB and gD for the Marek's disease virus, HN and F for the Newcastle disease virus, VP2 for the infectious bursal disease virus, S, M and N for the infectious bronchitis virus, C&plus;NS1 for the infectious anaemia virus.

Growing community of inventors

Lyons, France

Annabelle Bouchardon